Express Scripts' 2011 Drug Trend Report Reveals Strong Specialty Focus

Article

The specialty drug trend is projected to rise 17.1% in 2012, 19% in 2013, and 22% in 2014.

The specialty drug trend is projected to rise 17.1% in 2012, 19% in 2013, and 22% in 2014.

In 2011, 4 specialty classes—inflammatory conditions, multiple sclerosis (MS), cancer, and HIV—accounted for nearly 70% of spend for specialty drugs covered by pharmacy benefits, according to Express Scripts’ 2011 Drug Trend Report.

The report, which includes changes in prescription drug costs and utilization and provides insights on patient behaviors and market factors, is available for download now at http://express-scripts.com/research/research/dtr/. This year’s report focused on the waste that is produced by patient non-adherence and included an overview of the challenges, solutions, and trends that are expected with Medicare and Medicaid.

Many topics in the report have a strong specialty drug focus, especially in terms of the top 3 traditional therapy classes—inflammatory conditions, multiple sclerosis, and cancer. Specialty drugs saw greater cost increases, higher adherence, and a shift to higher cost therapies. Although the traditional drug trend is projected to be negative, the specialty drug trend is projected to rise 17.1% in 2012, 19% in 2013, and 22% in 2014. All of the top 10 classes in the analysis showed increases in total PMPY (per-member-per-year) medical spend, with trend for 4 classes exceeding 25%.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
Physician and kidneys
Image credit: gamjai - stock.adobe.com
Credit: warodom - stock.adobe.com
Male pharmacist in white coat with stethoscope and clipboard over drugstore background | Image Credit: Syda Productions - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.